ClinicalTrials.Veeva

Menu

DAratumumab and REvlimid REfractory MM

I

Institute of Hospitalization and Scientific Care (IRCCS)

Status

Enrolling

Conditions

Multiple Myeloma

Study type

Observational

Funder types

Other

Identifiers

NCT06541860
DARE-MM

Details and patient eligibility

About

Retrospective and prospective multicenter observational study on patients with relapsed and refractory multiple myeloma after anti-CD38 MoAb therapy and IMIDS treated with onlabel regimens.

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Phase I

  • Patients with RRMM after therapy with anti-CD38 MoAb plus IMIDS started on therapy with PVD scheme
  • Patients aged ≥ 18 years
  • Patients able to understand and voluntarily sign an informed consent and be willing to consent to the review of clinical data

Phase II

  • Patients with RRMM after first-line therapy with anti-CD38 MoAb plus IMIDS started on therapy with on-label schemes
  • Patients aged ≥ 18 years
  • Patients able to understand and voluntarily sign an informed consent and be willing to consent to the review of clinical data

Exclusion criteria

  • Patients not willing to consent to review of clinical data

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems